Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1800 participants
OBSERVATIONAL
2019-04-08
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlates of Protection in Ghana
NCT00138307
Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence in Ghana
NCT04301531
Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb
NCT00772642
Fetal Immunity to Falciparum Malaria
NCT00314899
Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana
NCT00857077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In order to identify interactions between parasite and host, a longitudinal study is performed starting with the recruitment of pregnant women. The study is conducted in Agogo in Ghana, an area with high malaria endemicity. The study design allows to analyse the neonatal immune status at birth, after potential in-utero exposure, and follows the development of immunity over the first 36 months of life. The current paradigm is that time points and frequency of infection as well as the type of variant surface antigen expressed have an impact on the cellular and humoral immune response to malaria, the development of clinical immunity, as well as the risk for future complications.
Starting point of the study is the antenatal care visit of mothers at Agogo Presbyterian Hospital (APH) during pregnancy. During recruitment, the mother will be asked to read and sign an informed consent form approved by the local ethical committee. After consent has been obtained from the mother, biological samples are taken, and a case report form is filled. An identification card with a unique code number is handed out. The first follow-up visit occurs at the birth of the child. At this time point, samples are taken from the mothers and the child. Mothers/primary caregivers are invited to observe the EPI visits offered at their nearest health post for further follow-ups. In the first year after birth, the EPI schedule includes visits at six weeks, ten weeks, 14 weeks, six months, and nine months. During these visits, questionnaires are completed and stool samples are taken. In the first six weeks after birth, the household is visited to complete a household questionnaire including housing characteristics and household assets. Additionally, a women's questionnaire is administered, which collects demographic and socioeconomic background characteristics as well as health and related behavioural data. At 12, 18, 24, and 36 months after birth, mothers/primary caregivers are encouraged to bring their children to the study hospital (APH) for a medical check-up. For the period of 36 months after birth, mothers/primary caregivers are strongly encouraged to visit the study hospital (APH) every time the child experiences a febrile illness or a history of fever in the last week during the observation period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mothers
900 mothers recruited during pregnancy
No interventions assigned to this group
Children
900 children born to the recruited mothers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willingness and able to give informed consent for herself and her child
Exclusion Criteria
* Positive HIV status of mother
* Refusal or withdrawal of informed consent
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kwame Nkrumah University of Science and Technology
OTHER
Kumasi Centre for Collaborative Research (KCCR)
OTHER
Heidelberg University
OTHER
KEMRI-Wellcome Trust Collaborative Research Program
OTHER
Agogo Presbyterian Hospital
UNKNOWN
Bernhard Nocht Institute for Tropical Medicine
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Jürgen May
Professor, Department Head
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jürgen May, Prof
Role: STUDY_DIRECTOR
Bernhard Nocht Institute for Tropical Medicine
John H Amuasi, Dr
Role: STUDY_DIRECTOR
Kwame Nkrumah University of Science & Technology (KNUST)
Eva Mertens, PhD
Role: PRINCIPAL_INVESTIGATOR
Bernhard Nocht Institute for Tropical Medicine
Nicole Struck, PhD
Role: PRINCIPAL_INVESTIGATOR
Bernhard Nocht Institute for Tropical Medicine
Oumou Maiga-Ascofaré, PhD
Role: PRINCIPAL_INVESTIGATOR
Kumasi Centre for Collaborative Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Agogo Presbyterian Hospital
Agogo, , Ghana
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PV5940
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.